2022 EANM指南:动脉内放射性化合物治疗肝癌和转移性肝癌

2022-02-17 Eur J Nucl Med Mol Imaging Eur J Nucl Med Mol Imaging

2022年2月,欧洲核医学协会(EANM)发布了动脉内放射性化合物治疗肝癌和转移性肝癌的操作指南。

2022年2月,欧洲核医学协会(EANM)发布了动脉内放射性化合物治疗肝癌和转移性肝癌的操作指南。原发性肝癌是全球范围内最常见的癌症之一,但仅有10%-20%的患者可以接受治疗。本文主要针对动脉内放射性化合物治疗肝癌和转移性肝癌的操作程序提供指导。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906470, encodeId=5e5019064e081, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 29 20:13:11 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218309, encodeId=5a221218309fb, content=哪里看文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Mon May 09 23:35:27 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386937, encodeId=f9b4138693ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Feb 19 00:13:11 CST 2022, time=2022-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906470, encodeId=5e5019064e081, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 29 20:13:11 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218309, encodeId=5a221218309fb, content=哪里看文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Mon May 09 23:35:27 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386937, encodeId=f9b4138693ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Feb 19 00:13:11 CST 2022, time=2022-02-19, status=1, ipAttribution=)]
    2022-05-09 杨三

    哪里看文章啊

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1906470, encodeId=5e5019064e081, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 29 20:13:11 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218309, encodeId=5a221218309fb, content=哪里看文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ42hR3zb89ZzkZVKorv74I6shMF3VlGLtBZczsr6uVSjeBF7ZAU2KLicPa2NekAOGfIglm1lDVwgA/132, createdBy=01945233793, createdName=杨三, createdTime=Mon May 09 23:35:27 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386937, encodeId=f9b4138693ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Feb 19 00:13:11 CST 2022, time=2022-02-19, status=1, ipAttribution=)]

相关资讯

日常吃点抗氧化剂强身健体?强的更可能是癌细胞的体!

Cell & Bioscience:抗氧化剂补充剂通过降低细胞内ROS和TMBIM1的诱导,促进肝癌的形成和生长,并使肝癌产生耐药性

陈敏山教授:2021年肝癌治疗进展年度盘点

对于肝癌的临床治疗与研究领域,注定2021年是不平凡的一年,多个治疗领域沉睡多年后获得重大进展,看到了新的希望。美国临床肿瘤学会(ASCO)和欧洲肿瘤内科学会(ESMO)公布了众多的肝癌治疗研究进展,

“神药”他汀再发威:不止抑制多种肝病进展,还可降低肝癌发生率!

Clinics in Liver Disease:他汀类药物有望抑制肝病的进展

戒酒总是戒不动?这份全国性酒精所致癌症负担报告了解一下?

2018年酒精消费占阿根廷所有癌症死亡人数的2.3%,占所有癌症DALY的2.1%。大多数死亡和残疾调整生命年可归因于适度饮酒,因为酗酒者只占人口的一小部分。

JGH: 慢性丙型肝炎患者接受直接抗病毒药物治愈后肝细胞癌复发的危险因素分析

丙型肝炎一般指丙型病毒性肝炎。 丙型病毒性肝炎,简称为丙型肝炎、丙肝,是一种由丙型肝炎病毒(HCV)感染引起的病毒性肝炎,主要经输血、针刺、吸毒等传播,据世界卫生组织统计,全球HCV的感染率约为3%。

卫健委发布新版肝癌诊疗指南,“七大”更新内容速度围观!

本文特此梳理了新版指南中的“七大”主要更新内容,以飨读者。